Table 2.
Odds Ratio for Fracture, Indirect Treatment Comparison Results of Drug versus Placebo Classical and Bayesian analysis
| Classical analysis | Non-vertebral fracture | Vertebral fracture | Hip fracture | Wrist fracture | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Drug vs placebo | OR (95% Cr I) |
Placebo rate |
OR (95% Cr I) |
Placebo rate |
OR (95% Cr I) |
Placebo rate |
OR (95% Cr I) |
Placebo rate |
|||||
| Alendronate | 0.80 (0.68, 0.95) | 11.1% | 0.51 (0.40, 0.63) | 6.7% | 0.62 (0.40, 0.96) | 1.1% | 0.44 (0.30, 0.67) | 3.0% | |||||
| Denosumab | 0.80 (0.67, 0.96) | 7.5% | 0.31 (0.24, 0.40) | 7.2% | 0.60 (0.37, 0.98) | 1.1% | NR | NR | |||||
| Etidronate | 0.64 (0.31, 1.32) | 11.5% | 0.59 (0.32, 1.10) | 9.7% | 0.60 (0.14, 2.66) | 2.1% | 1.19 (0.37, 3.80) | 2.2% | |||||
| Ibandronate | 0.88 (0.71, 1.10) | 7.5% | 0.49 (0.32, 0.73) | 7.5% | NR | NR | NR | NR | |||||
| Raloxifene | 0.91 (0.77, 1.07) | 9.3% | 0.63 (0.50, 0.78) | 10.1% | 1.12 (0.64, 1.95) | 0.7% | 0.88 (0.67, 1.15) | 3.3% | |||||
| Risedronate | 0.79 (0.69, 0.89) | 10.1% | 0.59 (0.47, 0.75) | 13.3% | 0.74 (0.58, 0.94) | 2.8% | 0.71 (0.56, 0.89) | 3.4% | |||||
| Strontium | 0.85 (0.74 (0.98) | 14.7% | 0.58 (0.50, 0.67) | 21.7% | 0.66 (1.19) | 4.0% | 1.59 (1.12, 2.27) | 3.2% | |||||
| Teriparatide | 0.62 (0.40, 0.97) | 9.7% | 0.31 (0.19, 0.52) | 14.3% | 0.50 (0.09, 2.75) | 0.7% | 0.50 (0.09, 2.75) | 2.4% | |||||
| Zoledronic Acid | 0.74 (0.63, 0.86) | 10.0% | 0.28 (0.22, 0.35) | 10.9% | 0.59 (0.83) | 2.3% | NR | NR | |||||
| All drugs vs placebo | 0.81 (0.77, 0.86) | 10.5% | 0.49 (0.41, 0.58) | 11.0% | 0.73 (0.63, 0.84) | 1.9% | 0.82 (0.71, 0.94) | 3.1% | |||||
| Bayesian analysis | Non-vertebral fracture | Vertebral fracture | Hip fracture | Wrist fracture | |||||||||
| Drug vs placebo | OR (95% Cr I) | Prob | Effect size |
OR (95% Cr I) | Prob | Effect size |
OR (95% Cr I) | Prob | Effect size |
OR (95% Cr I) | Prob | Effect size |
|
| Alendronate | 0.81 (0.66, 0.96) | 0.01 | 16.1 | 0.51 (0.37, 0.68) | < 0.01 | 25.3 | 0.59 (0.29, 0.99) | 0.10 | 9.49 | 0.93 (0.30, 2.64) | 0.10 | 1.80 | |
| Denosumab | 0.80 (0.60, 1.06) | 0.03 | 10.7 | 0.31 (0.21, 0.44) | 0.20 | 53.6 | 0.67 (0.24, 1.47) | 0.12 | 4.76 | NR | NR | NR | |
| Etidronate | 0.64 (0.31, 1.27) | 0.42 | 6.4 | 0.61 (0.29, 1.08 | 0.01 | 8.3 | 1.02 (0.12, 3.91) | 0.19 | 1.01 | 2.42 (0.25, 10.54) | 0.06 | 0.16 | |
| Ibandronate | 0.90 (0.69, 1.16) | < 0.01 | 9.3 | 0.50 (0.29, 0.78) | 0.01 | 16.1 | NR | NR | NR | NR | NR | NR | |
| Raloxifene | 0.91 (0.69, 1.20) | < 0.01 | 8.4 | 0.63 (0.43, 0.90) | 0.00 | 13.4 | 1.29 (0.45, 2.88) | 0.01 | 1.25 | 1.76 (0.09, 8.22) | 0.15 | 0.27 | |
| Risedronate | 0.77 (0.60, 0.91) | 0.04 | 16.4 | 0.60 (0.45, 0.79) | 0.00 | 19.3 | 0.78 (0.44, 1.32) | 0.01 | 5.71 | 0.91 (0.13, 3.27) | 0.22 | 1.37 | |
| Strontium | 0.86 (0.69, 1.07) | < 0.01 | 12.0 | 0.59 (0.45, 0.76) | < 0.01 | 21.8 | 0.98 (0.39, 2.01) | 0.01 | 2.47 | 3.25 (0.17, 14.89) | 0.06 | 0.08 | |
| Teriparatide | 0.62 (0.38, 1.02) | 0.41 | 9.9 | 0.32 (0.17, 0.57) | 0.30 | 29.8 | 0.71 (0.04, 2.90) | 0.44 | 1.93 | 1.23 (0.05, 5.64) | 0.41 | 0.57 | |
| Zoledronic Acid | 0.74 (0.56, 0.97) | 0.08 | 12.9 | 0.28 (0.19, 0.40) | 0.40 | 66.2 | 0.65 (0.25, 1.34) | 0.11 | 5.53 | NR | NR | NR | |
OR (95% Cr I): Odds ratio (95% Credibility Interval). Prob: probability of that drug being most efficacious.
Effect size evaluated as Odds ratio divided by corresponding standard error. NR: Not reported.